Research

Hormonal

Administration of the chimeric multi-agonist peptide GEP44 reduces body weight and energy intake in diet-induced obese mice primarily through a GLP-1 receptor (GLP-1R) dependent mechanism.

This research indicates that a new peptide drug called GEP44 can help reduce body weight and food intake in obese mice by targeting specific receptors in the brain. The effects rely heavily on the GLP-1 receptor, similar to drugs like Ozempic or Wegovy, but GEP44 also targets other receptors (Y1 and Y2). While promising in mice, this is preprint research and not yet available for human use.

ModerateSupportsMEDIUM confidence
These findings support the hypothesis that the chimeric peptide, GEP44, reduces energy intake, BW, core temperature, and glucose levels in male and female DIO mice primarily through a GLP-1R dependent mechanism.
James E. Blevins et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2024

Why this rating

The study is a preprint published on bioRxiv and has not been certified by peer review.

Source

The Novel Chimeric Multi-Agonist Peptide (GEP44) Reduces Energy Intake and Body Weight in Male and Female Diet-Induced Obese Mice in a Glucagon-Like Peptide-1 Receptor-Dependent Manner

James E. Blevins et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2024

DOI 10.1101/2024.05.17.594690

preprint
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →